Selfies with Kevin
She earned her (Doctorate) in education from the University of Delaware and is currently an English professor at Northern Virginia Community College.
Jill Biden
This company currently controls the largest market share within the MRD testing market.
Natera
This tool integrates the Recurrence Score with tumor grade, tumor size, and age and provides more prognostic information than the Recurrence Score alone.
RSClin
This company, which was recently acquired by Exact Sciences, offers blood-based next-generation sequencing therapy selection tests.
Resolution Bioscience
This is the first prospective, interventional study aimed to evaluate the diagnostic performance of an MCED test.
What is DETECT-A?
This American Journalist has worked for CNN, NBC, CBS, and ABC. She also underwent a colonoscopy on-air in March 2000.
Katie Couric
This is the type of genetic sequencing that will be used for version 2 of the Exact Sciences MRD assay.
Whole Genome Sequencing
This is the number of reference genes included in the Oncotype DX Breast Recurrence Score.
Five
City where Exact Sciences is planning to build a 250,000 square foot facility and create more than 800 jobs.
Phoenix, Arizona
This is the number of cancers that have a standard-of-care screening.
Harvard law school grad that has become famous for hosting the CNBC show Mad Money.
Jim Cramer
This country, in addition to the United States, is currently enrolling subjects in the CORRECT II observational study.
Canada
These midrange scores were used to classify a subject into the randomization arm of the TAILORx study.
11-25
This state is where Exact Sciences was founded in 1995 by Stanley Lapidus and Anthony Shuber.
**High Five for stating the city**
Massachusetts
This is the number of patients that remained cancer-free in the DETECT-A followup.
What is 97% (95 out of 98)
American lawyer and politician serving in the US house of representatives since 2011 for Alabama’s 7th congressional district.
Terri Sewell
These three labs are all a part of the CORRECT II MRD trial workflow (presented at our BiDS meeting by CAPE team)
Redwood City, Phoenix, Madison
The RxPONDER study established a chemotherapy benefit in this subgroup of women with scores between 0-25.
Premenopausal
This is the year that Exact Sciences first went public with an initial public offering on the NASDAQ stock exchange.
2001
In DETECT-A this is the number of cancer sites that were detected and had no standard of care screening
This legendary woman finished first in her class at Marquette University and is a Partner at Lake Effect Human Resources and Law in Madison Wisconsin.
Sheila Conroy
This is the parent study that is composed of one observational study called GALAXY and two randomized phase III trials called VEGA and ALTAIR.
CIRCULATE-Japan
This study established both the prognostic and predictive value of the Oncotype DX Breast Recurrence Score in node positive patients.
SWOG-8814
This healthcare information technology company was acquired by Exact Sciences in 2017 and was based in Salt Lake City, Utah.
Sampleminded
These 3 cancer types WILL NOT reach the target by the end of ASCEND-2 enrollment.
CRC, Lung, and Thyroid.